Tenaya Therapeutics TNYA

Tenaya Therapeutics, Inc. is a clinical stage biotechnology company committed to discovering developing and delivering potentially curative therapies for heart disease. The company focuses on gene therapy candidates TN-201 for MYBPC3 associated hypertrophic cardiomyopathy and TN-401 for PKP2 associated arrhythmogenic right ventricular cardiomyopathy. It also advances a small molecule program TN-301 a selective HDAC6 inhibitor with potential utility in heart failure with preserved ejection fraction and other cardiac metabolic muscular and pulmonary indications. Tenaya leverages internal capabilities in disease modeling capsid engineering promoter design and manufacturing to support its product pipeline.

The company currently generates revenue primarily through collaboration agreements research grants and upfront payments from partners. In March 2026 Tenaya entered into a research collaboration with Alnylam Pharmaceuticals that provides an upfront payment of up to ten million dollars and eligibility for milestone payments reaching up to 1.13 billion dollars upon achievement of development regulatory and sales targets. Additionally Tenaya received an eight million dollar clinical grant from the California Institute for Regenerative Medicine to support its RIDGE 1 clinical trial for TN-401. As a clinical stage biotech the company does not yet have product sales revenue but anticipates future income from commercialization of its gene therapy and small molecule candidates.

Tenaya Therapeutics occupies a focused niche in the precision medicine landscape for heart disease by targeting genetically defined subpopulations with disease modifying approaches. Its lead gene therapy candidates TN-201 and TN-401 compete with symptomatic treatments such as Bristol Myers Squibbs Camzyos and Cytokinetics Myqorzo for hypertrophic cardiomyopathy and with device based therapies for arrhythmogenic right ventricular cardiomyopathy. For its HDAC6 inhibitor TN-301 the company faces competition from approved heart failure agents like Novartis Entresto Lilly and Boehringer Ingelheim Jardiance Astra Zeneca Farxiga and Lilly Tirzepatide as well as from Duchenne muscular dystrophy therapies such as Italfarmaco Duvyzat. Tenaya differentiates itself through an integrated platform that combines human induced pluripotent stem cell disease models capsid engineering proprietary promoter constructs and in house manufacturing capabilities which enable rapid target validation and efficient production of gene therapy vectors. This vertically integrated approach reduces reliance on external contractors and enhances control over product quality and timelines giving the company a competitive advantage in advancing its pipeline.

Tenaya Therapeutics serves patients suffering from genetic cardiomyopathies heart failure with preserved ejection fraction Duchenne muscular dystrophy and other cardiac muscular and pulmonary conditions. The company also engages with pharmaceutical partners such as Alnylam with whom it has a research collaboration to discover and validate novel gene targets for cardiovascular disease. Additionally Tenaya works with academic investigators and clinical trial sites including leading cardiology centers in the United States and the United Kingdom to conduct its MyPEAK 1 RIDGE 1 and other studies. These relationships provide access to patient populations and support the development and potential commercialization of its product candidates.